Our pharmaceutical products
Depending on the specific territory in question, dossiers and Marketing Authorizations (MAs) may be readily available, currently under development, or can be developed in strategic partnership to effectively address particular market opportunities that may arise.
List of Dossiers / Marketing Autorisation available in EU
The following dossiers and Marketing Authorisations are either currently under development or already available, depending on the country of interest. We would also welcome the opportunity to partner with you on the development of dossiers for specific countries or regions, should there be a mutual interest and market opportunity. Please let us know which territories are of interest to you, and we would be pleased to discuss the available options in more detail.
Semaglutide - generics of RYBELSUS®
Key Strength : 3 mg, 7 mg, 14 mg -
Therapeutic area : Type 2 Diabetes and chronic weight management.
Targeting the fastest-growing segment in oral GLP-1 therapies are expanding at 18–24% CAGR, with strong demand for cost-effective oral alternatives
Availability : licensing-ready asset aligned for market entry as global patent cliffs begin in 2026.
Glycerol Phenyl Butrate - generics of RAVICTI®
Key Strength: 1.1 g/mL oral solution
Therapeutic area: Urea Cycle Disorders (UCDs) – chronic ammonia control therapy
Targeting: Targeting a rare disease market with high unmet medical need, glycerol phenylbutyrate provides long-term ammonia management in pediatric and adult UCD patients. The asset benefits from orphan-drug positioning, limited competition, and premium pricing across Europe and international markets.
Availability: Licensing-ready specialty asset for UCD management, supported by a completed EU dossier with remaining bridging/comparison activities.
Perampanel - generics of FYCOMPA®
Key Strength: 0.5 mg/mL oral suspension
Therapeutic area: Epilepsy – partial-onset seizures and generalized tonic-clonic seizures
Targeting: Targeting the growing epilepsy treatment market, perampanel offers a differentiated oral liquid formulation suitable for pediatric, geriatric, and dysphagic patients. Increasing demand for patient-centric formulations continues to drive adoption as adherence and individualized therapy become key healthcare priorities.
Availability: Licensing-ready CNS asset supported by a completed dossier, with opportunity to leverage existing reference product data.
Pimozide - generics of ORAP®
Key Strength: 1 mg, 2 mg tablets
Therapeutic area: Tourette syndrome and tic disorders (CNS)
Targeting: Targeting a niche but stable neurological market, pimozide remains a clinically established treatment option in Tourette syndrome where therapeutic alternatives are limited. Demand is steady with long-term usage in selected patient populations.
Availability: Mature dossier asset with European bioequivalence study pending.
Calcitriol - generics of ®
Key Strength: 0.25 mcg, 0.5 mcg soft gel capsules
Therapeutic area: Endocrinology / Nephrology – secondary hyperparathyroidism, hypocalcemia, CKD-related mineral and bone disorders
Targeting: Targeting the growing chronic kidney disease (CKD) patient population, calcitriol remains a core active vitamin D analog widely used in hospital and outpatient settings. Sustained demand is driven by increasing CKD prevalence, aging populations, and long-term mineral bone disorder management requirements.
Availability: Established specialty generic asset with mature lifecycle and consistent long-term demand across global markets.
Ergocalciferol - generics of ®
Key Strength: 50,000 IU soft gel capsules
Therapeutic area: Vitamin D deficiency and metabolic bone disorders
Targeting: Targeting the expanding vitamin D supplementation market, ergocalciferol addresses widespread deficiency across adult and elderly populations. Growing awareness of preventive healthcare and bone health continues to support long-term stable demand.
Availability: Licensing-ready vitamin D therapy with completed dossier and EU bioequivalence activities pending.
Apixaban - generics of ELIQUIS®
Key Strength: 2.5 mg, 5 mg tablets
Therapeutic area: Cardiovascular – anticoagulation (stroke prevention in atrial fibrillation, treatment and prevention of DVT/PE)
Targeting: Targeting one of the largest and fastest-growing cardiovascular generic opportunities, driven by the global loss of exclusivity of Eliquis. The direct oral anticoagulant (DOAC) market continues to expand due to aging populations, rising atrial fibrillation prevalence, and sustained shift from vitamin K antagonists to safer, fixed-dose oral therapies.
Availability: Licensing-ready generic asset positioned for multi-regional market entry aligned with upcoming patent expiries and accelerating DOAC market expansion.
Eltrombopag pFoS- generics of PROMACTA®
Key Strength: 12.5 mg, 25 mg equivalent oral suspension
Therapeutic area: Hematology – immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia management
Targeting: Targeting a high-value specialty hematology market, eltrombopag benefits from increasing global demand for thrombopoietin receptor agonists. The oral suspension format provides a differentiated patient-centric solution for pediatric and dysphagic populations, expanding access beyond conventional tablet-based therapies. Patent expiries and accelerating generic penetration are expected to unlock strong multi-regional opportunities.
Availability: Development-stage specialty generic asset with dossier completion anticipated in late 2026, aligned with post-exclusivity market entry opportunities.
Eltrombopag tablets- generics of PROMACTA®
Key Strength: 12.5 mg, 25 mg, 50 mg, 75 mg tablets
Therapeutic area: Hematology – immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia-associated disorders
Targeting: Targeting a high-value specialty hematology market, eltrombopag is positioned as one of the largest upcoming post-exclusivity opportunities in thrombopoietin receptor agonists. Growth is supported by increasing diagnosis rates, high treatment costs, and expanding patient access initiatives across Europe and international markets.
Availability: Licensing-ready specialty generic asset aligned with post-exclusivity market entry, with dossier completion expected in late 2026.
Aliskiren Hemifumarate - generics of TEKTURNA®
Key Strength: 150 mg, 300 mg tablets
Therapeutic area: Cardiovascular – essential hypertension (direct renin inhibition)
Targeting: Targeting the antihypertensive market segment requiring renin-angiotensin system modulation, aliskiren remains the only marketed direct renin inhibitor, offering differentiated clinical positioning within a highly competitive cardiovascular class. Demand is driven by the large global hypertension population and ongoing need for alternative mechanisms of action in resistant or uncontrolled cases.
Availability: Licensing-ready cardiovascular generic asset with dossier completion expected in 2026, positioned for selective international market opportunities.
Glipizide - generics of GLUCOTROL®
Key Strength: 2.5 mg, 5 mg, 10 mg tablets
Therapeutic area: Type 2 Diabetes Mellitus – oral sulfonylurea antidiabetic therapy
Targeting: Targeting the large and continuously expanding global Type 2 diabetes population, glipizide remains a widely used cost-effective treatment option, particularly in price-sensitive healthcare systems and emerging markets. Its established clinical profile and broad physician familiarity support sustained demand in long-standing diabetes management protocols.
Availability: Mature generic asset with well-established global market presence and consistent long-term demand across multiple regions.
Givionstat - generics of DUVYZAT®
Key Strength: 8.86 mg/mL oral suspension
Therapeutic area: Rare disease / Neuromuscular disorders – Duchenne Muscular Dystrophy (DMD)
Targeting: Targeting the high-value orphan disease segment, givinostat is positioned within the Duchenne Muscular Dystrophy treatment landscape, addressing key inflammatory and fibrotic pathways involved in disease progression. The market is driven by increasing diagnosis rates, strong unmet medical need, and the emergence of disease-modifying therapies in rare neuromuscular disorders.
Availability: Licensing-ready rare disease specialty asset with dossier availability expected in 2026, aligned with orphan-drug market entry opportunities and limited competitive landscape.
Our orthopedic product portfolio
At our company, we take pride in offering a diverse range of pharmaceutical products designed to meet your healthcare needs. Each product in our selection reflects our commitment to quality, efficacy, and safety. We understand the importance of reliable healthcare solutions, which is why we ensure that every item is thoroughly tested and meets stringent industry standards. Browse through our offerings to find detailed descriptions, features, and specifications that will help you make informed choices. Whether you are looking for everyday essentials, specialised treatments, or innovative solutions, we have something to cater to every requirement and preference.
Body belts & braces
Fracture Aids
Cervical Aids
Physio-Therapy
Ankle Support
Knee Supports
Allied Products
Wrist & Forearm
Neoprene Products
Compression Garments
Silicone & Foot Care Products
Finger Splints
Child Range
Traction Kits
Hot & Cold-Therapy
OAC Products
Walking Aids
Your Collection
If you're interested in adding your products to our platform, it couldn't be simpler! All you need to do is reach out to us directly. Our team is ready to assist you with the process and ensure that your products are showcased effectively. Just contact us and we will guide you through the necessary steps to get your products listed. We value your contributions and look forward to collaborating with you to enhance our offerings!
Créez votre propre site internet avec Webador